Brii Biosciences Reports Promising Phase 2 Results

Brii Biosciences Limited (HK:2137) has released an update.

Brii Biosciences Limited has announced promising results from its Phase 2 ENSURE study, showcasing the potential of elebsiran in combination with pegylated interferon alpha to achieve higher hepatitis B virus (HBV) seroclearance rates. The study revealed that elebsiran significantly outperformed the interferon therapy alone, indicating its potential as a key component in developing a functional cure for chronic HBV. This development could attract investor interest as the company continues to advance clinical trials and explores new combination therapies.

For further insights into HK:2137 stock, check out TipRanks’ Stock Analysis page.